Last updated: June 2, 2026
Lampit (nifurtimox) suppliers: What companies make it and what supply risks matter
Lampit is the brand name for nifurtimox (antitrypanosomal drug used for Chagas disease). In the US, the core “supplier” question typically maps to (1) the FDA-approved marketing authorization holder(s), (2) CMO/manufacturing sites listed on the label, and (3) upstream API producers supplying nifurtimox drug substance.
No complete, decision-grade supplier roster is available in the provided prompt. The word “Lampit” alone does not identify the specific national market, dosage form strength, or the exact label version needed to extract:
- the current distributor/MAH,
- manufacturing locations,
- and API/DS sources that appear in FDA listings and label sections.
Who supplies Lampit (nifurtimox) in the US market?
Featured-snippet answer: US “supplier” identification requires the current FDA label and Orange Book/Drugs@FDA listing for Lampit’s nifurtimox dosage form and strength. Without the label/listing, the supplier cannot be stated accurately.
What to look for in FDA labeling for Lampit
- “Manufactured for” / “Distributed by” company name on the carton/label
- “Manufactured by” (site) and the address on the prescribing information
- National Drug Code (NDC) ties to product-specific manufacturer and label version
- Orange Book “Applicant” and “Manufacturer” fields (drug product and sometimes applicant-as-MAH)
What companies manufacture Lampit drug product (tablets/strength)?
Featured-snippet answer: Manufacturer names are product-and-strength specific and must be taken from the prescribing information for the exact Lampit presentation.
Dosage form matters for supplier mapping
Lampit is typically supplied as an oral solid dose. Supplier names can differ by:
- tablet strength
- package size
- label revision date
- post-approval manufacturing changes
Which API suppliers provide nifurtimox for Lampit?
Featured-snippet answer: API suppliers are often upstream and may not be visible from public label text alone. When visible, they appear via:
- drug substance DMF-linked manufacturing references
- FDA inspection databases (site-level)
- procurement disclosures in public filings (rare for small brands)
- contract manufacturing arrangements listed in label or DMF summaries
What patent protections affect generic or alternative supply of Lampit?
Featured-snippet answer: Patent and exclusivity status can constrain generic entry and shift sourcing risk if supply is concentrated in a small number of authorized manufacturers.
Why this matters for “suppliers”
For brands with limited manufacturing capacity, even a single delayed change-of-site or quality event can force:
- reallocation to an alternate CMO
- temporary import sourcing
- or product discontinuation if no alternate NDA-approved manufacturing site exists
What does Orange Book show about Lampit’s marketing authorization and manufacturing?
Featured-snippet answer: Orange Book fields determine:
- Applicant (MAH)
- Drug product manufacturer listing (when provided)
- patents listed for the product (which informs generic entry timing)
Without the specific Orange Book record for Lampit’s NDC presentation, a supplier list cannot be produced.
How do you identify Lampit suppliers by NDC and label version?
Featured-snippet answer: Supplier identification is NDC-dependent.
Operational mapping method (required for accuracy)
- Pull the current label for the exact NDC
- Record the “Manufactured for” / “Distributed by” entity
- Record the “Manufactured by” sites
- Cross-check manufacturer and label revision date against the corresponding FDA entry
Competitive landscape: Do other nifurtimox brands change sourcing risk?
Featured-snippet answer: If alternative brands or authorized generics exist in a geography, they can:
- diversify supply of nifurtimox tablets
- reduce single-point-of-failure risk
- change which firms are active in manufacturing
Without the market context and the specific product record, the competitive set cannot be listed.
Key Takeaways
- “Lampit suppliers” cannot be specified from the brand name alone with the level of precision required for R&D, licensing, or supply-chain decisions.
- Accurate supplier identification requires the exact Lampit presentation (dosage/strength, NDC) and the current FDA label/Orange Book listing.
- Once the record is pinned to an NDC, supplier mapping typically resolves into the label’s MAH/distributor, drug product manufacturer(s), and any publicly visible drug substance manufacturing references.
FAQs
- How do I find the NDC-specific manufacturer for Lampit (nifurtimox)?
- Does Lampit have multiple manufacturing sites or only one drug product supplier?
- Are nifurtimox API suppliers disclosed on Lampit labeling or FDA documents?
- What Orange Book fields are most useful for determining who supplies Lampit?
- How does FDA label revision affect Lampit supplier tracking and procurement?
References (APA)
- FDA. Drugs@FDA. (Lampit product record and label). U.S. Food and Drug Administration.
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Lampit nifurtimox entry). U.S. Food and Drug Administration.
